Tyra Biosciences price target raised to $28 from $25 at Oppenheimer

Oppenheimer raised the firm’s price target on Tyra Biosciences to $28 from $25 and keeps an Outperform rating on the shares following the company’s Q1 earnings results. The firm noted that it has recently noticed an uptick in investor interest in the story, which it feels “isn’t surprising as we approach initial data from SURF301 later this year.”